^
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
VRD Resistant: B - Late Trials
|
VRD Resistant: B - Late Trials
|
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
lenalidomide + ixazomib Sensitive: C3 – Early Trials
|
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
bortezomib Resistant: C3 – Early Trials
|
bortezomib Resistant: C3 – Early Trials
|
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
venetoclax Resistant: D – Preclinical
|
venetoclax Resistant: D – Preclinical
|
